methyldopa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors 1762 555-30-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methyldopa (levorotatory)
  • methyldopa
  • aldochlor
  • aldomine
  • alphamethyldopa
  • lederdopa
  • (-)-alpha-Methyl-3,4-dihydroxyphenylalanine
An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.
  • Molecular weight: 211.22
  • Formula: C10H13NO4
  • CLOGP: -2.26
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 103.78
  • ALOGS: -1.97
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O
1 g P
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 157.66 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.69 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.90 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GRK3,GSK3B,IGF1R,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM1,PIM2,PLK1,PRKCD,PRKDC,PTK2,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 79
kinase-selectivity-class ACVR2B,AXL,BMX,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,MAPK8,PRKDC,STK33,SYK,TEK,TGFBR1 19
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 1962 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature delivery 1898.20 26.32 507 10154 38255 90579531
Exposure during pregnancy 1455.69 26.32 655 10006 237755 90380031
Maternal exposure during pregnancy 1361.18 26.32 712 9949 359351 90258435
Foetal exposure during pregnancy 971.32 26.32 309 10352 42666 90575120
Premature baby 825.76 26.32 241 10420 24836 90592950
Pre-eclampsia 574.17 26.32 152 10509 10896 90606890
Low birth weight baby 415.37 26.32 114 10547 9353 90608433
Foetal growth restriction 374.95 26.32 105 10556 9275 90608511
Caesarean section 315.95 26.32 108 10553 18469 90599317
Oligohydramnios 284.98 26.32 80 10581 7121 90610665
Live birth 280.04 26.32 151 10510 78956 90538830
Patent ductus arteriosus 247.43 26.32 65 10596 4504 90613282
HELLP syndrome 231.37 26.32 48 10613 1169 90616617
Premature labour 228.32 26.32 78 10583 13298 90604488
Atrial septal defect 205.37 26.32 64 10597 8170 90609616
Small for dates baby 172.77 26.32 50 10611 4957 90612829
Normal newborn 166.11 26.32 72 10589 23290 90594496
Gestational diabetes 150.96 26.32 54 10607 10528 90607258
Conjoined twins 143.10 26.32 28 10633 502 90617284
Polyhydramnios 113.63 26.32 31 10630 2477 90615309
Placental insufficiency 111.02 26.32 28 10633 1647 90616139
Ventricular septal defect 109.99 26.32 36 10625 5371 90612415
Intestinal malrotation 98.94 26.32 20 10641 426 90617360
Hypotonia neonatal 95.25 26.32 24 10637 1406 90616380
Neonatal respiratory distress syndrome 93.94 26.32 28 10633 3073 90614713
Premature rupture of membranes 93.20 26.32 32 10629 5526 90612260
Neonatal respiratory failure 93.11 26.32 18 10643 302 90617484
Proteinuria 92.28 26.32 48 10613 23243 90594543
Selective eating disorder 86.64 26.32 24 10637 2029 90615757
Neonatal seizure 81.33 26.32 18 10643 599 90617187
Congenital bladder anomaly 79.61 26.32 15 10646 218 90617568
Urachal abnormality 79.11 26.32 15 10646 226 90617560
Persistent cloaca 78.32 26.32 15 10646 239 90617547
Gliosis 73.93 26.32 16 10645 479 90617307
Gestational hypertension 72.99 26.32 23 10638 3039 90614747
Drug-induced liver injury 72.76 26.32 70 10591 90248 90527538
Foetal death 71.63 26.32 39 10622 20684 90597102
Premature separation of placenta 70.13 26.32 21 10640 2341 90615445
Polyserositis 69.03 26.32 16 10645 657 90617129
Pouchitis 68.94 26.32 16 10645 661 90617125
Ureteric stenosis 68.14 26.32 16 10645 696 90617090
Congenital choroid plexus cyst 68.10 26.32 14 10647 325 90617461
Respiratory disorder neonatal 66.66 26.32 18 10643 1383 90616403
Abortion spontaneous 61.63 26.32 51 10610 54005 90563781
Hypoglycaemia neonatal 60.91 26.32 16 10645 1106 90616680
Ultrasound uterus abnormal 60.75 26.32 10 10651 62 90617724
Foetal distress syndrome 58.69 26.32 17 10644 1688 90616098
Premature menopause 58.22 26.32 16 10645 1313 90616473
Exposure via breast milk 57.73 26.32 18 10643 2297 90615489
Microcephaly 57.58 26.32 16 10645 1368 90616418
Stillbirth 56.36 26.32 24 10637 7419 90610367
Retrognathia 55.69 26.32 13 10648 551 90617235
Ovarian failure 54.87 26.32 16 10645 1627 90616159
Ovarian cyst 52.76 26.32 30 10631 17288 90600498
Newborn persistent pulmonary hypertension 52.28 26.32 11 10650 287 90617499
Neonatal asphyxia 50.11 26.32 11 10650 352 90617434
Infantile haemangioma 50.08 26.32 9 10652 99 90617687
Antiphospholipid syndrome 49.74 26.32 16 10645 2258 90615528
Rash 49.66 26.32 16 10645 796084 89821702
Phaeochromocytoma 49.38 26.32 12 10649 605 90617181
Toxoplasmosis 45.02 26.32 14 10647 1771 90616015
Proctectomy 44.15 26.32 9 10652 200 90617586
Maternal exposure during breast feeding 43.63 26.32 19 10642 6201 90611585
Maternal condition affecting foetus 43.26 26.32 9 10652 222 90617564
Somatic symptom disorder 43.25 26.32 16 10645 3425 90614361
Venous thrombosis limb 43.15 26.32 16 10645 3446 90614340
Cerebellar hypoplasia 41.86 26.32 8 10653 126 90617660
Adiposis dolorosa 40.50 26.32 9 10652 305 90617481
Renal hypertension 39.68 26.32 8 10653 168 90617618
Pneumonia 39.45 26.32 13 10648 638046 89979740
Pregnancy 38.85 26.32 42 10619 62005 90555781
Cardiac tamponade 38.84 26.32 17 10644 5615 90612171
Peripartum cardiomyopathy 37.97 26.32 8 10653 210 90617576
Congenital hydronephrosis 37.56 26.32 9 10652 427 90617359
Foetal exposure timing unspecified 37.30 26.32 9 10652 440 90617346
Fatigue 37.18 26.32 49 10612 1153974 89463812
Abdominal discomfort 36.85 26.32 6 10655 477322 90140464
Hypersensitivity 36.75 26.32 5 10656 454672 90163114
Breech presentation 36.47 26.32 11 10650 1256 90616530
Dysmorphism 36.22 26.32 13 10648 2555 90615231
Hypertonia neonatal 36.01 26.32 8 10653 271 90617515
Diarrhoea 34.38 26.32 36 10625 939154 89678632
Preterm premature rupture of membranes 33.67 26.32 11 10650 1630 90616156
Diaphragmatic paralysis 33.38 26.32 9 10652 687 90617099
Maternal exposure before pregnancy 33.02 26.32 19 10642 11194 90606592
Neonatal hypoxia 32.95 26.32 9 10652 722 90617064
Alopecia 32.55 26.32 9 10652 495062 90122724
Delayed fontanelle closure 32.20 26.32 5 10656 20 90617766
Arthropathy 32.17 26.32 3 10658 366239 90251547
Drug intolerance 31.63 26.32 7 10654 447584 90170202
Oliguria 31.28 26.32 18 10643 10606 90607180
Blood pressure inadequately controlled 31.04 26.32 15 10646 6209 90611577
Congenital cerebral cyst 30.78 26.32 7 10654 264 90617522
Blood pressure diastolic increased 30.54 26.32 19 10642 12887 90604899
Infusion related reaction 30.51 26.32 6 10655 416774 90201012
Ileostomy closure 29.98 26.32 7 10654 297 90617489
Foetal disorder 29.89 26.32 7 10654 301 90617485
Abortion induced 29.40 26.32 18 10643 11870 90605916
Bradyarrhythmia 29.31 26.32 11 10650 2450 90615336
Cervical incompetence 29.31 26.32 8 10653 640 90617146
Foetal heart rate deceleration abnormality 28.94 26.32 8 10653 671 90617115
Bicuspid aortic valve 28.84 26.32 6 10655 148 90617638
Swelling 28.72 26.32 7 10654 419051 90198735
Vaginal haemorrhage 28.55 26.32 26 10635 31245 90586541
Joint swelling 28.16 26.32 12 10649 503288 90114498
Maternal drugs affecting foetus 27.46 26.32 13 10648 5142 90612644
Posterior reversible encephalopathy syndrome 27.39 26.32 22 10639 22317 90595469
Glossodynia 27.30 26.32 3 10658 321776 90296010
Congenital aortic valve stenosis 27.13 26.32 5 10656 64 90617722
Death 26.99 26.32 10 10651 456541 90161245
Renal failure neonatal 26.95 26.32 6 10655 205 90617581
Malaise 26.89 26.32 18 10643 585968 90031818
Decreased appetite 26.37 26.32 6 10655 376534 90241252

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal exposure during pregnancy 1378.80 45.15 390 3613 46921 42570411
Premature baby 1082.43 45.15 278 3725 22875 42594457
Low birth weight baby 698.14 45.15 166 3837 9789 42607543
Atrial septal defect 401.98 45.15 102 3901 7817 42609515
Small for dates baby 348.75 45.15 84 3919 5179 42612153
Foetal growth restriction 292.52 45.15 73 3930 5210 42612122
Hypospadias 257.27 45.15 61 3942 3506 42613826
Patent ductus arteriosus 217.43 45.15 53 3950 3423 42613909
Respiratory disorder neonatal 175.43 45.15 40 3963 1930 42615402
Large for dates baby 163.06 45.15 33 3970 897 42616435
Infantile apnoea 162.23 45.15 34 3969 1102 42616230
Ventricular septal defect 157.38 45.15 43 3960 4356 42612976
Hypoglycaemia neonatal 150.96 45.15 36 3967 2114 42615218
Selective eating disorder 142.01 45.15 33 3970 1731 42615601
Foetal disorder 140.93 45.15 30 3973 1049 42616283
Diabetic foetopathy 139.07 45.15 23 3980 191 42617141
Neonatal respiratory distress syndrome 137.97 45.15 39 3964 4474 42612858
Maternal exposure during pregnancy 129.44 45.15 41 3962 6937 42610395
Neutropenia neonatal 105.59 45.15 23 3980 897 42616435
Congenital hydronephrosis 103.17 45.15 22 3981 775 42616557
Neonatal respiratory failure 99.96 45.15 19 3984 369 42616963
Bradycardia neonatal 91.66 45.15 22 3981 1326 42616006
Caesarean section 91.43 45.15 24 3979 2082 42615250
Maternal drugs affecting foetus 89.98 45.15 27 3976 3812 42613520
Pulmonary hypoplasia 82.77 45.15 17 3986 497 42616835
Exposure during pregnancy 68.81 45.15 27 3976 8521 42608811
Hypotonia neonatal 64.84 45.15 17 3986 1467 42615865
Cryptorchism 64.11 45.15 18 3985 2009 42615323
Foetal heart rate deceleration abnormality 63.79 45.15 14 3989 565 42616767
Hydrops foetalis 62.71 45.15 15 3988 890 42616442
Pulmonary valve stenosis congenital 62.44 45.15 11 3992 137 42617195
Apgar score low 56.68 45.15 14 3989 951 42616381
Microcephaly 52.09 45.15 13 3990 921 42616411
Congenital cystic lung 51.37 45.15 10 3993 221 42617111
Bronchopulmonary dysplasia 49.63 45.15 12 3991 745 42616587
Foetal distress syndrome 49.01 45.15 13 3990 1173 42616159
Ureteric stenosis 48.29 45.15 13 3990 1241 42616091
Acoustic stimulation tests abnormal 48.19 45.15 8 3995 68 42617264
Pyelocaliectasis 46.79 45.15 13 3990 1396 42615936
Eyelid ptosis congenital 46.24 45.15 8 3995 89 42617243
Supernumerary nipple 45.22 45.15 7 3996 36 42617296

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature delivery 1650.50 23.28 404 8877 30228 110549790
Exposure during pregnancy 1508.03 23.28 553 8728 166871 110413147
Maternal exposure during pregnancy 1389.47 23.28 585 8696 254298 110325720
Pre-eclampsia 603.73 23.28 141 9140 8509 110571509
Live birth 337.55 23.28 148 9133 69336 110510682
Caesarean section 277.28 23.28 84 9197 13733 110566285
Oligohydramnios 256.97 23.28 61 9220 3933 110576085
Premature labour 219.90 23.28 64 9217 9108 110570910
Premature baby 210.45 23.28 54 9227 4801 110575217
Foetal growth restriction 198.38 23.28 47 9234 3003 110577015
HELLP syndrome 180.94 23.28 35 9246 841 110579177
Normal newborn 179.63 23.28 68 9213 21828 110558190
Gestational diabetes 152.83 23.28 46 9235 7343 110572675
Placental insufficiency 122.08 23.28 27 9254 1267 110578751
Polyhydramnios 116.43 23.28 28 9253 1905 110578113
Foetal exposure during pregnancy 114.41 23.28 37 9244 7468 110572550
Premature rupture of membranes 100.79 23.28 30 9251 4607 110575411
Drug-induced liver injury 83.84 23.28 74 9207 119993 110460025
Proteinuria 83.13 23.28 48 9233 39970 110540048
Gestational hypertension 78.30 23.28 21 9260 2213 110577805
Stillbirth 77.33 23.28 24 9257 4240 110575778
Abortion spontaneous 76.26 23.28 43 9238 34239 110545779
Foetal death 73.97 23.28 33 9248 16012 110564006
Gliosis 73.07 23.28 16 9265 716 110579302
Ovarian failure 68.49 23.28 16 9265 960 110579058
Polyserositis 67.57 23.28 16 9265 1018 110579000
Premature menopause 67.45 23.28 16 9265 1026 110578992
Pouchitis 62.79 23.28 16 9265 1381 110578637
Oesophageal atresia 59.54 23.28 10 9271 104 110579914
Premature separation of placenta 56.07 23.28 15 9266 1565 110578453
Antiphospholipid syndrome 53.43 23.28 16 9265 2507 110577511
Teratogenicity 51.73 23.28 10 9271 239 110579779
Somatic symptom disorder 49.88 23.28 16 9265 3143 110576875
Phaeochromocytoma 49.65 23.28 12 9269 833 110579185
Ultrasound uterus abnormal 48.52 23.28 7 9274 23 110579995
Maternal condition affecting foetus 47.95 23.28 9 9272 183 110579835
Maternal exposure during breast feeding 45.27 23.28 16 9265 4222 110575796
Adiposis dolorosa 43.53 23.28 9 9272 305 110579713
Proctectomy 42.61 23.28 9 9272 339 110579679
Venous thrombosis limb 41.89 23.28 16 9265 5249 110574769
Toxoplasmosis 41.47 23.28 14 9267 3225 110576793
Cardiac tamponade 38.91 23.28 19 9262 11288 110568730
Abortion induced 38.59 23.28 17 9264 8002 110572016
Ovarian cyst 37.98 23.28 20 9261 13910 110566108
Vaginal haemorrhage 36.55 23.28 24 9257 25050 110554968
Peripartum cardiomyopathy 35.39 23.28 7 9274 189 110579829
Oliguria 35.11 23.28 21 9260 18636 110561382
Low birth weight baby 34.56 23.28 9 9272 846 110579172
Umbilical cord vascular disorder 33.69 23.28 5 9276 21 110579997
Diabetic foetopathy 33.14 23.28 5 9276 24 110579994
Blood pressure inadequately controlled 32.95 23.28 15 9266 7618 110572400
Posterior reversible encephalopathy syndrome 32.23 23.28 25 9256 33836 110546182
Ileostomy closure 30.90 23.28 7 9274 366 110579652
Diaphragmatic paralysis 30.87 23.28 9 9272 1285 110578733
Blood pressure diastolic increased 29.87 23.28 19 9262 18788 110561230
Preterm premature rupture of membranes 29.47 23.28 9 9272 1506 110578512
Pregnancy 28.87 23.28 28 9253 51039 110528979
Salivary gland cancer stage IV 28.60 23.28 5 9276 67 110579951
Renal artery stenosis 28.48 23.28 11 9270 3715 110576303
Cervical incompetence 28.24 23.28 7 9274 540 110579478
Postpartum haemorrhage 27.51 23.28 9 9272 1880 110578138
Hypertension 26.98 23.28 99 9182 509985 110070033
Intestinal transit time decreased 25.61 23.28 5 9276 126 110579892
Bradyarrhythmia 25.50 23.28 11 9270 4923 110575095
Ileostomy 25.43 23.28 9 9272 2383 110577635
Ventricular hypertrophy 24.72 23.28 12 9269 7033 110572985
Intestinal anastomosis 24.47 23.28 7 9274 934 110579084
Blood pressure diastolic abnormal 24.44 23.28 19 9262 25796 110554222
Maternal exposure before pregnancy 24.37 23.28 12 9269 7253 110572765
Azotaemia 23.37 23.28 13 9268 10072 110569946
Death 23.30 23.28 15 9266 698854 109881164
Blood albumin decreased 23.29 23.28 19 9262 27633 110552385

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neonatal respiratory failure 36.59 23.97 33 1601 291 112028

Pharmacologic Action:

SourceCodeDescription
ATC C02AB01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Methyldopa
ATC C02AB02 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Methyldopa
ATC C02LB01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Methyldopa and diuretics in combination
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013565 Sympatholytics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
CHEBI has role CHEBI:35569 alpha-adrenergic agonists
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:49110 peripheral nervous system drugs
CHEBI has role CHEBI:59174 haptens
CHEBI has role CHEBI:66991 sympatholytic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Cirrhosis of liver contraindication 19943007 DOID:5082
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Acute hepatitis contraindication 37871000
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hypomagnesemia contraindication 190855004
Angina pectoris contraindication 194828000
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Neonatal hyperbilirubinemia contraindication 281610001
Pheochromocytoma contraindication 302835009
Hypertriglyceridemia contraindication 302870006
Autoimmune hemolytic anemia contraindication 413603009 DOID:718
Porphyria contraindication 418470004
Azotemia contraindication 445009001
Severe Cerebrovascular Disease contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.51 acidic
pKa2 8.98 acidic
pKa3 13.39 acidic
pKa4 10.04 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR AGONIST WOMBAT-PK CHEMBL
Aromatic-L-amino-acid decarboxylase Enzyme WOMBAT-PK
Epidermal growth factor receptor Kinase IC50 5.28 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.29 DRUG MATRIX
Lysine-specific demethylase 4E Enzyme IC50 5.52 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.67 DRUG MATRIX

External reference:

IDSource
4017896 VUID
N0000146248 NUI
D08205 KEGG_DRUG
4017896 VANDF
C0025741 UMLSCUI
CHEBI:61058 CHEBI
CHEMBL459 ChEMBL_ID
DB00968 DRUGBANK_ID
D008750 MESH_DESCRIPTOR_UI
38853 PUBCHEM_CID
56LH93261Y UNII
6876 RXNORM
1035 MMSL
5088 MMSL
d00133 MMSL
000646 NDDF
373542000 SNOMEDCT_US
84078002 SNOMEDCT_US
41372-08-1 SECONDARY_CAS_RN
56LH93261Y INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 21695-879 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 21695-880 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 42254-351 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 54868-0050 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 54868-1328 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 62135-321 TABLET, FILM COATED 250 mg ORAL NDA authorized generic 11 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 62135-322 TABLET, FILM COATED 500 mg ORAL NDA authorized generic 11 sections
Methyldopa Human Prescription Drug Label 1 64980-571 TABLET 250 mg ORAL ANDA 20 sections
Methyldopa Human Prescription Drug Label 1 64980-572 TABLET 500 mg ORAL ANDA 20 sections
Methyldopa HUMAN PRESCRIPTION DRUG LABEL 1 68151-2791 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections